azelastine hydrochloride + beclomethasone dipropionate

This drug is a **fixed-dose combination** of two active pharmaceutical ingredients: **azelastine hydrochloride**, an intranasal second-generation antihistamine, and **beclomethasone dipropionate**, a synthetic corticosteroid. Azelastine acts as an antagonist of the histamine H1 receptor and possesses additional mast cell stabilizing and anti-allergic properties, blocking histamine-induced symptoms and potentially inhibiting the release of inflammatory mediators such as interleukins and leukotrienes. Beclomethasone dipropionate acts as a corticosteroid receptor agonist, blocking multiple inflammatory pathways by binding to the glucocorticoid receptor, reducing local inflammation via inhibition of cytokine and mediator release. This combination is designed for **intranasal** administration to provide complementary antihistaminic and anti-inflammatory effects for relief of symptoms of allergic rhinitis, especially when monotherapy is inadequate. Clinical trials have evaluated its **relative bioavailability and pharmacokinetics**, and both drugs are individually approved for allergic rhinitis and related nasal conditions[7][1][5].

Brand names

No widely established unique brand name found for this fixed-combination. Some trial/commercial products may exist under national brands, but major global brand not identified in public data.

Other names

fixed dose combination azelastine hydrochloride / beclomethasone dipropionate